Drug Profile
Research programme: melanocortin peptides - Mallinckrodt
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Questcor Pharmaceuticals
- Developer Mallinckrodt plc
- Class Peptides
- Mechanism of Action Melanocortin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 28 Jul 2018 No recent reports of development identified for preclinical development in Inflammation in USA
- 14 Aug 2014 Questcor Pharmaceuticals has been acquired by Mallinckrodt plc